Black Diamond Therapeutics, Inc.
BDTX · United States
Share price · BDTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BDTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-14.2%
- 26 Oct 2026-10.1%
Nothing announced by BDTX that day or the session before.
- 23 Oct 2026-9.6%
Nothing announced by BDTX that day or the session before.
- 20 Oct 2026+14.4%
Nothing announced by BDTX that day or the session before.
- 24 Jun 2026+15.5%
Nothing announced by BDTX that day or the session before.
- 22 May 2026-35.8%
- 20 May 2026+20.0%
Nothing announced by BDTX that day or the session before.
- 19 May 2026+16.3%
Nothing announced by BDTX that day or the session before.
- 8 May 2026+9.9%
- 15 Apr 2026+7.9%
Nothing announced by BDTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of BDTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Silevertinibevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 10% |
| Other company news (earnings, financing, releases naming no asset) | — | 14% |
| Sessions with no dated event | — | 76% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | EGFRSmall molecule | Non-Small Cell Lung CancerGlioblastoma Non-Small Cell Lung Cancer with EGFR Mutations, Recurrent Glioblastoma with EGFR Alterations |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
March 2028 (1)
What to watch
November 2028 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $7.0M | $16M+ $87M short-term inv. | $10M-$8.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $7.4M | $20M+ $91M short-term inv. | $9.9M-$8.0M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $7.0M | $31M+ $88M short-term inv. | $9.0M-$10M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $7.4M | $32M+ $105M short-term inv. | $8.5M-$7.8M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $9.3M | $31M+ $113M short-term inv. | $11M-$9.2M operating cash flow | report ↗ |
| 2025-Q1 | $70M | $11M | $99M+ $54M short-term inv. | —$53M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $13M | $24M+ $89M short-term inv. | $16M-$11M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $13M | $34M+ $90M short-term inv. | $20M-$15M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $14M | $26M+ $90M short-term inv. | $18M-$21M operating cash flow | report ↗ |
| 2023-Q3 | — | $16M | $59M+ $86M short-term inv. | $23M-$18M operating cash flow | report ↗ |
| 2023-Q2 | — | $13M | $43M+ $48M short-term inv. | $19M-$14M operating cash flow | report ↗ |
| 2023-Q1 | — | $15M | $40M+ $64M short-term inv. | $21M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $16M | $55M+ $90M short-term inv. | $22M-$16M operating cash flow | report ↗ |
| 2022-Q2 | — | $16M | $57M+ $105M short-term inv. | $23M-$18M operating cash flow | report ↗ |
| 2022-Q1 | — | $18M | $55M+ $126M short-term inv. | $26M-$29M operating cash flow | report ↗ |
| 2021-Q3 | — | $28M | $48M+ $188M short-term inv. | $35M-$26M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $70M | $34M | $22M+ $108M short-term inv. | —$30M operating cash flow | report ↗ |
For fiscal year 2025, Black Diamond Therapeutics reported revenue of $70M, compared with $0M in the prior year, reflecting the upfront payment from the Servier license. R&D expense was $33.56M, down 34.6% YoY, and the company ended the year with $21.82M in cash and equivalents and net income of $22.37M.
The company’s lead candidate, silevertinib, is in a Phase 2 trial in EGFR-mutant non-small cell lung cancer; initial frontline data announced in December 2025 showed a 60% objective response rate, 86% CNS response rate, and 91% disease control rate at the November 3, 2025 cutoff, with updated duration of response and progression-free survival results planned for the second quarter of 2026. A randomized Phase 2 trial in newly diagnosed EGFR-altered glioblastoma is expected to begin in the second quarter of 2026. BDTX-4933 was outlicensed to Servier in the first quarter of 2025, with eligibility for up to $710M in milestone payments and tiered royalties, and the company continues to evaluate partnerships for silevertinib and strategic alternatives for BDTX-4876.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $51M | $37M+ $62M short-term inv. | $17M-$62M operating cash flow | report ↗ |
| 2023-FY | — | $59M | $57M+ $75M short-term inv. | $21M-$67M operating cash flow | report ↗ |
| 2022-FY | — | $64M | $35M+ $88M short-term inv. | $23M-$85M operating cash flow | report ↗ |
| 2021-FY | — | $97M | $67M+ $144M short-term inv. | $31M-$100M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-18 | Behbahani Ali · director | Award / grant | 7,707 | $1.93 | $15K | Form 4 |
| 2026-09-18 | Raman Prakash · director | Award / grant | 6,801 | $1.93 | $13K | Form 4 |
| 2026-06-26 | Campbell Shannon · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-26 | Dhingra Kapil · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-26 | Raman Prakash · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-26 | Menzel Garry E · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-26 | Kulkarni Samarth · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-26 | Behbahani Ali · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 103 reporting institutions held 38.5M shares ($54.2M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | NEA Management Company, LLC | 4,448,757 | $9.5M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,850,468 | $3.9M |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1,643,747 | $3.5M |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1,301,664 | $2.8M |
| 5 | BlackRock, Inc. | 1,106,840 | $2.4M |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 1,058,397 | $2.3M |
| 7 | MACKENZIE FINANCIAL CORP | 844,835 | $1.8M |
| 8 | MARSHALL WACE, LLP | 836,266 | $1.8M |
| 9 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 834,570 | $1.8M |
| 10 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 723,477 | $1.5M |
| 11 | GOLDMAN SACHS GROUP INC | 684,418 | $1.5M |
| 12 | FMR LLC | 623,827 | $1.3M |
| 13 | UBS Group AG | 564,838 | $1.2M |
| 14 | Man Group plc | 559,700 | $1.2M |
| 15 | WINTON GROUP Ltd | 538,259 | $1.1M |